<DOC>
	<DOCNO>NCT00266786</DOCNO>
	<brief_summary>Ketorolac market several year form ( tablet injectable ) short-term relief pain . This study test whether new dosage form ( nasal spray ) contain ketorolac effective relieving pain major abdominal surgery , also assess product safety . Previous study nasal spray suggest similar previously approve injectable form effectiveness pain relief safety profile . Patients randomize 2:1 ratio receive intranasal ketorolac placebo pain reach moderate level ( 40 scale 100 ) follow surgery . After first dose , subject receive study drug every 6 hour 48 hour , need ( 4 time day ) total 5 day . If pain adequately relieve study drug , subject give morphine sulfate standard analgesic . Follow-up safety evaluation occur 1 2 week start dose . Subjects ask answer question pain relief possible side effect drug study , give physical examination , include nasal evaluation , clinical trial . A small amount blood drawn routine clinical laboratory testing .</brief_summary>
	<brief_title>Safety Efficacy Multiple Doses Intranasal Ketorolac Postoperative Pain Following Major Abdominal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Men woman age 18 64 year Major abdominal surgery Body weight ≥ 100 ≤ 300 pound Negative serum pregnancy test Pain intensity score least 40 ( moderate pain ) 100 mm visual analog scale Minimum 48 hour hospital stay 5 day maximum stay Able provide write informed consent Willing able comply test requirement protocol Allergy sensitivity ketorolac ethylene diamine tetraacetic acid ( EDTA ) Allergy significant reaction opioids Allergic reaction aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Current upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray adverse event assessment Use intranasal product past 24 hour Clinically significant abnormality screen lab test History cocaine use Active peptic ulcer disease significant history peptic ulcer disease gastrointestinal bleeding Advanced renal impairment risk renal failure History medical problem could interfere study participation Pregnancy breastfeed Participation another investigational study within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>